Search Results

EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine.

EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016.

Suggestions that the U.S. should emulate other countries on drug price controls or patents obscure how our present policies have allowed drug development to flourish.

EMulate Therapeutics, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia.

Emulate, Inc., the leading provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.

EMulate Therapeutics announced that Chris Rivera will present an overview of current results and future plans for EMTx at the Life Science Innovation Northwest 2023.

EMulate Therapeutics, Inc. today announced the addition of Donna Morgan Murray, Ph.D. to the Company’s board of directors.

Emulate, Inc., a leading provider of next-generation in vitro models, announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.

Emulate, Inc. today announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%.